Zhang Kaijiong, Luo Zhenglian, Zhang Yi, Zhang Li, Wu Lichun, Liu Lian, Yang Jie, Song Xiaoyu, Liu Jinbo
Department of Laboratory Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Department of Laboratory Medicine, Sichuan Cancer Hospital, Chengdu, Sichuan, China.
Cancer Biomark. 2016 Jun 24;17(2):187-94. doi: 10.3233/CBM-160630.
Long non-coding RNA (lncRNA) H19 has been well studied playing an important role in breast cancer (BC) progress and the expression of H19 may service as a diagnostic target for BC. However, it is unclear if circulating lncRNA H19 could as a potential biomarker for BC diagnosis and monitor.
The objective of our study was to determine whether plasma lncRNA H19 could be used as biomarkers for the screening and early diagnosis of breast cancer.
In this study, we carried out a quantitative real-time PCR (qRT-PCR) method to examine the expression levels of lncRNA H19 in 24 pairs of BC tissues and 20 pairs of BC plasma. The differentially expressed of plasma H19 was further validated in another 102 BC patients and 96 healthy controls. The potential correlations between plasma H19 levels and clinicopathological characteristics were analyzed. Receiver operating characteristic (ROC) curve was performed to evaluate the diagnostic values of plasma H19 between 30 early stage BC patients and 30 healthy controls. 24 paired pre- and postoperative plasma samples were detected to assess the tumor monitoring values.
The results revealed that the expression of H19 was significantly increased in BC tissues and plasma compared with healthy controls (P< 0.05), and plasma H19 levels were significantly correlated with estrogen receptor (ER) (P= 0.008), progesterone receptor (PR) (P= 0.025), c-erbB-2 (P= 0.043) and lymph node metastasis (P= 0.006). The area under the ROC curve (AUC) of plasma H19 was 0.81(sensitivity, 56.7%; specificity, 86.7%; P< 0.0001), which was higher than the values of carcinoembryonic antigen (CEA) and carbohydrate antigen 153 (CA153). Furthermore, plasma H19 levels were significantly decreased in postoperative samples than preoperative samples (P= 0.0006).
Plasma H19 may serve as a potential biomarker for BC early screening and prognosis monitor.
长链非编码RNA（lncRNA）H19在乳腺癌（BC）进展中的重要作用已得到充分研究，H19的表达可能作为BC的诊断靶点。然而，尚不清楚循环lncRNA H19是否可作为BC诊断和监测的潜在生物标志物。
本研究的目的是确定血浆lncRNA H19是否可作为乳腺癌筛查和早期诊断的生物标志物。
在本研究中，我们采用定量实时PCR（qRT-PCR）方法检测24对BC组织和20对BC血浆中lncRNA H19的表达水平。在另外102例BC患者和96例健康对照中进一步验证血浆H19的差异表达。分析血浆H19水平与临床病理特征之间的潜在相关性。绘制受试者工作特征（ROC）曲线，评估30例早期BC患者和30例健康对照之间血浆H19的诊断价值。检测24对术前和术后血浆样本，评估肿瘤监测价值。
结果显示，与健康对照相比，BC组织和血浆中H19的表达显著增加（P<0.05），血浆H19水平与雌激素受体（ER）（P=0.008）、孕激素受体（PR）（P=0.025）、c-erbB-2（P=0.043）和淋巴结转移（P=0.006）显著相关。血浆H19的ROC曲线下面积（AUC）为0.81（敏感性，56.7%；特异性，86.7%；P<0.0001），高于癌胚抗原（CEA）和糖类抗原153（CA153）的值。此外，术后样本中血浆H19水平明显低于术前样本（P=0.0006）。
血浆H19可能作为BC早期筛查和预后监测的潜在生物标志物。
